Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Pancreatic cancer secreted targets and uses thereof

a pancreatic cancer and target technology, applied in the field of molecular markers and therapeutic agents, can solve the problems of difficult differentiation between benign pancreatic diseases, poor prognosis of pancreatic cancer, and low survival rate of all cancers

Inactive Publication Date: 2008-09-11
CELERA CORPORATION
View PDF1 Cites 7 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Benefits of technology

The present invention provides a method for diagnosing or detecting pancreatic disease by measuring the level of one or more pancreatic cancer-associated secreted target (PCAST) proteins, peptides, or nucleic acids in a sample from a subject. The PCAST proteins are differentially expressed in pancreatic cancer and can be used as markers for diagnosis or detection of the disease. The invention also provides monoclonal or polyclonal antibodies that specifically bind to the PCAST proteins. The invention further provides a method for screening for agents that modulate the activity of PCAST proteins and for agents that bind to the PCAST proteins. The PCAST proteins can be used for diagnosis and monitoring of pancreatic disease progression and treatment progress.

Problems solved by technology

The prognosis for pancreatic carcinoma is, at present, very poor, it displays the lowest five-year survival rate among all cancers.
Despite the advances in diagnostic imaging methods like ultrasonography (US), endoscopic ultrasonography (EUS), dualphase spiral computer tomography (CT), magnetic resonance imaging (MRT), endoscopic retrograde cholangiopancreatography (ERCP) and transcutaneous or EUS-guided fine-needle aspiration (FNA), distinguishing pancreatic carcinoma from benign pancreatic diseases, especially chronic pancreatitis, is difficult because of the similarities in radiological and imaging features and the lack of specific clinical symptoms for pancreatic carcinoma.
Secreted APPs modulate neuronal excitability, counteract effects of glutamate on growth cone behaviors, and increase synaptic complexity.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Examples

Experimental program
Comparison scheme
Effect test

working examples

1. Pancreatic Cell Line Model System

[0369]Analysis of gene expression in various pancreatic cancer cell lines as well as pancreatic duct epithelial tissue has shown that the cell line Hs766T correlates well with normal tissue. For this reason, this cell line is reported in the literature as being a good surrogate for normal tissue in analyses of differential expression between pancreatic adenomcarcinoma (and derived tumor lines) and normal tissue (or surrogate, Hs766T). The model system employed here involves the use of Hs766T as a “normal” reference to which secreted expression in tumor-derived cell lines is compared. These differentials or candidates are then validated in tissues, pancreatic cancer and normal pancreas, to confirm that they are differentially expressed between these tissues as well as within the cell line model system. Details of the pancreatic tumor lines that were used for this study, as well as the pancreatic line Hs766T are provided below.

Cell Lines and Media:

[...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
pHaaaaaaaaaa
temperaturesaaaaaaaaaa
temperatureaaaaaaaaaa
Login to View More

Abstract

The present invention provides a method for diagnosing and detecting diseases associated with pancreas. The present invention provides one or more proteins or fragments thereof, peptides or nucleic acid molecules differentially expressed in pancreatic diseases (PCAST) and antibodies binds to PCAST. The present invention provides that PCAST is used as targets for screening agents that modulates the PCAST activities. Further the present invention provides methods for treating diseases associated with pancreas.

Description

FIELD OF THE INVENTION[0001]This invention relates to the fields of molecular biology and oncology. Specifically, the invention provides a molecular marker and a therapeutic agent for use in the diagnosis and treatment of cancers.BACKGROUND OF THE INVENTION[0002]Cancer currently constitutes the second most common cause of death in the United States. Carcinomas of the pancreas are the eighth most prevalent form of cancer and fourth among the most common causes of cancer deaths in this country.[0003]The prognosis for pancreatic carcinoma is, at present, very poor, it displays the lowest five-year survival rate among all cancers. Such prognosis results primarily from delayed diagnosis, due in part to the fact that the early symptoms are shared with other more common abdominal ailments. Despite the advances in diagnostic imaging methods like ultrasonography (US), endoscopic ultrasonography (EUS), dualphase spiral computer tomography (CT), magnetic resonance imaging (MRT), endoscopic ret...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(United States)
IPC IPC(8): A61K39/395A61P35/00C07K14/47A61K38/17C12N15/12C12Q1/68G01N33/566C07K16/18C12N5/16C12N5/10
CPCG01N33/57438C07K14/4748A61P35/00
Inventor ALVING, KIMRUBEN, STEVEMCCAFFERY, IANDOMON, BRUNO
Owner CELERA CORPORATION
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com